

Povetacept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis


James Tumlin^{1,2}, Harmeet Singh³, Frank Cortazar⁴, Arvind Madan⁵, Jonathan Barratt⁶, Brad Rovin⁷, Hong Zhang⁸, Rupert Davies⁹, Amanda Enstrom⁹, Allison Chunyk⁹, Heather Thomas⁹, Jiahua Li⁹, Stanford L. Peng⁹, and Sreedhar Mandayam¹⁰

¹NephroNet Clinical Trials Consortium, Atlanta, GA; ²Emory University School of Medicine, Atlanta, GA; ³Western Nephrology, Arvada, CO; ⁴New York Nephrology Vasculitis and Glomerular Center, Albany, NY; ⁵Central Florida Kidney Specialists, Orlando, FL; ⁶University of Leicester, Leicester, UK; ⁷The Ohio State University, Columbus, OH; ⁸Peking University First Hospital, Beijing, China; ⁹Alpine Immune Sciences, Inc., Seattle, WA; ¹⁰University of Texas MD Anderson Cancer Center, Houston, TX.

Poster TH-PO1125
Abstract 3977579

INTRODUCTION



- BAFF and APRIL play critical, overlapping, and non-redundant roles in the activation, differentiation, and/or survival of B cells (particularly antibody-secreting cells) and other immune cell types.^{1,2}
- Inhibition of BAFF and/or APRIL has shown promise in multiple glomerulonephritis conditions,³⁻⁸ with the potential to modify the underlying pathogenic autoimmunity.
- Povetacept (ALPN-303) is an Fc fusion of a variant TACI domain engineered for more potent dual BAFF/APRIL inhibition than wild-type TACI-Ig or anti-BAFF or anti-APRIL antibodies.⁹
- In multiple preclinical disease models, povetacept demonstrated activity superior to wild-type TACI-Ig; BAFF-, APRIL-, or FcRn-specific inhibitors; and B-cell depletion.⁹⁻¹¹
- In healthy volunteers, povetacept was well tolerated and induced on-target PD effects, including reduced circulating Ig levels (including the IgAN biomarker Gd-IgA1) and antibody-secreting cells.¹²



STUDY DESIGN & STATUS


RUBY-3 (NCT05732402) is an ongoing, first-in-disease, open-label, multiple ascending dose, phase 1b/2a study of povetacept in adults with glomerulonephritis, including IgAN, pMN, and LN.

RUBY-3 Study Schema and Disposition and Analysis Status: IgAN Cohorts



RESULTS

KEY RESULTS: Low Dose Povetacept (80 mg SC Q4W) in IgA Nephropathy



Baseline Characteristics for IgAN Cohort Treated with Low Dose Povetacept (80 mg SC Q4W)

Characteristic (Mean \pm SD or N [%])	80 mg SC Q4W N=12
Age, yr	51 \pm 12
Female / Male	7 (58%) / 5 (42%)
Caucasian / Asian	7 (58%) / 5 (42%)
BMI, kg/m ²	28 \pm 6.5
Duration of Disease, yr	4.4 \pm 6.5
24-hr UPCR, g/g	1.3 \pm 0.8
eGFR, mL/min/1.73 m ²	70 \pm 35
Prior Treatments	
- Corticosteroids	2 (17%)
- Eculizumab	1 (8%)
Current SGLT2 Inhibitor Use	2 (17%)
Medical History	
- Hypertension	7 (58%)
- Diabetes	4 (33%)

Data: 20 Oct 2023

Low Dose Povetacept (80 mg SC Q4W) Has Been Well Tolerated in IgAN

- Treatment-emergent AEs during treatment with povetacept 80 mg SC Q4W have been low grade to date, with none considered treatment-related.
- No administration-related reactions, severe infections or severe hypogammaglobulinemia (IgG < 3 g/L).

Status	80 mg SC Q4W N=12
Treatment-Emergent AEs (n, %)	4 (33%)
- Grade 1	3 (25%)
- Grade 2	1 (8%)
- Grade \geq 3	0
- Treatment-related	0
AEs of Interest (n, %)	
- Administration-related reaction	0
- Hypogammaglobulinemia (IgG < 3 g/L)	0
- Grade \geq 3 infection	0
Any Infection	2 (17%) ^a

^a Grade 1 nasopharyngitis, n=1; grade 2 upper respiratory tract infection, n=1. Data: 20 Oct 2023

REFERENCES

- Samy E. Int Rev Immunol. 2017;36(1):3-19.
- Benson MJ. J Immunol. 2008;180(6):3655-3659.
- Barratt J. Kidney Int Rep. 2022;7(8):1831-1841.
- Lv J. Kidney Int Rep. 2023;8(3):499-506.
- Kooienga L. J Am Soc Nephrol. 2022;33:TH-PO991 [ASN22].
- Barratt J. Nephrol Dial Transplant. 2023;38:4337 [ERA23].
- Furie R. N Engl J Med. 2020;383(12):1117-1128.
- Chen J-W. Int J Rheum Dis. 2023;26(7):1417-1421.
- Evans LS. Arthritis Rheumatol. 2023;75(7):1187-1202.
- Blair T. Abs 2350 [ACR23].
- Dillon SR. Abs 207 [AANEM23].
- Dillon SR. Abs ide078 [IgANN23].
- Bagchi S. Kidney Int Rep. 2021;6(6):1661-1668.
- Francis JM. Am J Kidney Dis. 2016;68(1):138-147.

ABBREVIATIONS

ACEi, angiotensin-converting enzyme inhibitor; AE, adverse event; AEI, AE of interest; APRIL, a proliferation-inducing ligand; ARB, angiotensin receptor blocker; BAFF, B cell activating factor; BMI, body mass index; eGFR, estimated glomerular filtration rate; FcRn, neonatal Fc receptor; Gd-IgA1, galactose-deficient IgA1; IFTA, interstitial fibrosis and tubular atrophy; Ig, immunoglobulin; IgAN, IgA nephropathy; LN, lupus nephritis; PD, pharmacodynamics; pMN, primary membranous nephropathy; Q4W, once every 4 weeks; SC, subcutaneous; SGLT2, sodium-glucose cotransporter 2; TACI, transmembrane activator and CAML interactor; UPCR, urine protein to creatinine ratio.

Low-Dose Povetacept in pMN: A Case of Immunological Remission (Ongoing)


Primary Membranous Nephropathy¹⁴

- PLA2R1 is the major target antigen (up to 80%)
- Anti-PLA2R1 is highly correlated with clinical outcome
- Resolution of proteinuria lags behind immunological remission by months

First and only participant with pMN enrolled to date:

- 70-yr-old African-American male
- Duration of disease: 0.4 yr
- Current treatment: lisinopril

Data: 25 Oct 2023




Immunological remission (anti-PLA2R1 reduced to below the limit of detection) at wk 22

SUMMARY/CONCLUSIONS

- Low-dose povetacept (80 mg SC Q4W) has been well tolerated with multiple dosing.
- In participants with IgAN, low-dose povetacept demonstrates very promising activity at 6 months, with > 50% reduction in UPCR, > 60% reduction in Gd-IgA1, and consideration of clinical remission.
- In a first and ongoing case of pMN, immunological remission was observed at 22 wk.
- Higher-dose povetacept (240 mg SC Q4W) is currently being evaluated.
- These findings suggest a highly promising clinical profile for povetacept (based on initial clinical and biomarker activity and dose schedule) and strongly support further development in glomerulonephritis, particularly IgAN.

To obtain a copy of this poster, please scan the QR code.

SCAN ME



ACKNOWLEDGEMENTS

We thank all participants of the RUBY-3 study and their families, as well as the investigators and staff at study sites, for their contributions to this work.

The RUBY-3 study is sponsored and funded by Alpine Immune Sciences, Inc. Support for graphical illustrations was provided by Jennifer Austin of Biocrat Studio. We also appreciate the contributions from the RUBY-3 study team and other colleagues to the generation of these analyses and the development of this presentation.